TRIM11 and non-small cell lung carcinoma: On the other hand, an AMPK agonist (20 nM of Ampkinone) reduced cell proliferation and EDU cells, increased cell metastasis, and decreased caspase‐3/9 activity levels in NSCLC with downregulated TRIM11 gene expression (as depicted in Figure 5F–J).